Trial · NCT05919797
Weight Loss Study: Genetics and Response to Naltrexone/Bupropion
NCT05919797, Phase 4, Recruiting, Columbia University
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Weight Loss Study: Genetics and Response to Naltrexone/Bupropion. Trials, record NCT05919797. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05919797
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Weight Loss Study: Genetics and Response to Naltrexone/Bupropion
- NCT number
- NCT05919797
- Status
- Recruiting
- Phases
- Phase 4
- Enrollment
- 120 participants, estimated
- Lead sponsor
- Columbia University
- Conditions
- Obesity
- Interventions
- Naltrexone-Bupropion Combination
- First posted
- 2023-06-26
- Last updated
- 2026-06-10
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percent Weight Loss (40 Weeks) | Baseline and 40 Weeks | Percent weight loss from baseline to 40 weeks. |
| Secondary | Percent Excess Weight Loss | Baseline and 40 Weeks | Percent excess weight loss defined as \[(initial weight - weight lost at week 40)/(initial weight - weight at a BMI 25kg/m2)\] x 100 |
| Secondary | Percent Excess Weight Loss | 12 Weeks and 40 Weeks | Percent excess weight loss defined as \[(Week 12 weight - weight lost at week 40)/(initial weight - weight at a BMI 25kg/m2)\] x 100 |
| Secondary | Percent of Participants Achieving ≥ 5% Weight Loss | Baseline and 40 Weeks | Percent of participants achieving ≥ 5% weight loss at week 40 |
| Secondary | Percent of Participants Achieving ≥ 10% Weight Loss | Baseline and 40 Weeks | Percent of participants achieving ≥ 10% weight loss at week 40 |
| Secondary | Percent Weight Loss | 12 weeks and 40 weeks | Percent weight loss from 12 weeks to 40 weeks. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| R01DK132527 | Association of genetic variation near the dopamine D2 receptor gene and other polymorphisms that modulate dopaminergic and opioid signaling on the weight loss response to naltrexone/bupropion | KORNER, JUDITH | COLUMBIA UNIVERSITY HEALTH SCIENCES | NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES | 2023 to 2025 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05919797
GET https://conductscience.org/api/trials/v1/NCT05919797/registered